



Monkeypox Vaccine Development and Vaccination Strategies

Guest Editors:

Dr. Natalie Prow

Hull York Medical School,
University of York, York, UK

Dr. Preethi Eldi

Experimental Therapeutics
Laboratory, Clinical and Health
Science Unit, University of South
Australia, Adelaide, SA, Australia

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

Monkeypox is a zoonotic disease that was once endemic in west and central Africa, caused by the orthopoxvirus, monkeypox virus. However, recent cases have been confirmed in many nonendemic countries outside of Africa. The WHO declared the ongoing monkeypox outbreak to be a public health emergency of international concern on 23 July 2022. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets and via fomites such as towels and bedding. Strategies for prevention, such as the smallpox vaccine has been recommended in high-risk persons. Two vaccines are currently available, JYNNEOSTM (live, replication-incompetent vaccinia virus) and ACAM2000® (live, replication-competent vaccinia virus). The development of vaccines against the monkeypox virus and different vaccination strategies are urgently needed. In this context, this Special Issue invites you to submit your research related to scientific advances in the field of monkeypox vaccine development and vaccination strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com